LifeVantage Corporation (Nasdaq:LFVN), a leading health and
wellness company with products designed to activate optimal health
processes, today announced that Company scientists have completed a
study on the impact Protandim® Nrf2 Synergizer® and TrueScience®
Liquid Collagen have on cellular health. The study results showed
that when combined, the products work together to help cells
accurately respond to stress levels and recover more quickly,
supporting the body’s immune function.
“When cells are stressed they send out signals
asking for help from the immune system,” explained Lisa Barnes,
Vice President of Research & Development. “However, even after
the stressor is eliminated, it can be common for this signaling to
continue, causing the immune system to waste precious energy trying
to fix a problem that no longer exists. This unchecked cycle can
lead to significant health concerns. The synergistic benefits of
Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen, help
break this repetitive stress cycle by reducing unnecessary
signaling, allowing cells to get back to their optimal function,
which in this case is producing collagen.”
Barnes continued, “The study shows why people
are seeing such incredible results with these two products.
Together, they create a potent combination that drives cellular
rebalance, helping to ensure cells are functioning properly. It’s
like sending your cells to a day at the spa, like the effect people
are trying to achieve with ice plunges or cryotherapy. It’s amazing
how these two products work with your body to support its natural
functions.”
“The results of this study are further proof
that LifeVantage’s unique emphasis on activation provides the
optimal approach to health and wellness,” said Steve Fife,
President, and Chief Executive Officer. “Our products are clearly
differentiated and have demonstrated their effectiveness in
amplifying the body’s natural processes to improve health starting
at the cellular level. The science behind our products is one of
the pillars of LifeVantage’s competitive strength and supports the
compelling business opportunity we offer for entrepreneurial minded
individuals.”
Scientific Investigation Spurred by the
Consumer ExperienceThe study was designed after consumers
provided significant anecdotal evidence about unexpected, positive
results in gut health, joint health, along with improvements in
overall energy and clarity. To understand why, Barnes and team
devised a study in three parts: a dose-finding study, a gene
expression study to verify dose timing and concentration, and a
global gene expression study using RNA sequencing.
Specifically, the study looked at the products'
influence on fibroblasts. Found throughout the body, fibroblasts
produce and organize components of the skin that act as the
scaffold or support for the skin through proteins, including
collagen, elastin, and laminin. Fibroblasts not only produce
collagen and other proteins that make up the extracellular matrix
for the skin, but they also perform the same function for other
organs, such as the intestines, spleen, brain, lung, liver, kidney,
and blood vessels.
The gene expression study showed 13,195 genes
distributed over 18,671 cellular pathways were influenced in the
fibroblasts. Around 21% (2,786 genes) were significantly up, or
downregulated either by Protandim Nrf2 Synergizer®, TrueScience®
Liquid Collagen, or a combination of the two. Of the 2,786 genes
measured, the combination of the two products synergistically
influenced 2,439 genes (p<0.05), of which 418 genes (17%) were
significantly up- (195 genes) or downregulated (223 genes).
These statements have not been evaluated by the
Food and Drug Administration. These products are not intended to
diagnose, treat, cure, or prevent any disease.
About LifeVantage
CorporationLifeVantage Corporation (Nasdaq: LFVN), the
activation company, is a pioneer in nutrigenomics, the study of how
nutrition and naturally occurring compounds affect human genes to
support good health. The Company engages in the identification,
research, development, formulation and sale of advanced
nutrigenomic activators, dietary supplements, nootropics, pre- and
probiotics, weight management, skin and hair care, bath & body,
and targeted relief products. The Company’s line of
scientifically-validated dietary supplements includes its flagship
Protandim® family of products, LifeVantage® Omega+, ProBio, IC
Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary
supplements, the TrueScience® line of skin, hair, bath & body,
and targeted relief products. The Company also markets and sells
Petandim®, its companion pet supplement formulated to combat
oxidative stress in dogs, Axio® its nootropic energy drink mixes,
and PhysIQ, its smart weight management system. LifeVantage was
founded in 2003 and is headquartered in Lehi, Utah. For more
information, visit www.lifevantage.com.
Cautionary Note Regarding Forward
Looking StatementsThis document contains forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words and
expressions reflecting optimism, satisfaction or disappointment
with current prospects, as well as words such as "believe," "will,"
"hopes," "intends," "estimates," "expects," "projects," "plans,"
"anticipates," "look forward to," "goal," “may be,” and variations
thereof, identify forward-looking statements, but their absence
does not mean that a statement is not forward-looking. The
declaration and/or payment of a dividend during any quarter
provides no assurance as to future dividends, and the timing and
amount of future dividends, if any, could vary significantly in
comparison both to past dividends and to current expectations.
Examples of forward-looking statements include, but are not limited
to, statements we make regarding executing against and the benefits
of our key initiatives, future growth, including geographic and
product expansion, the impact of COVID-19 on our business, expected
financial performance, and expected dividend payments in future
quarters. Such forward-looking statements are not guarantees of
performance and the Company's actual results could differ
materially from those contained in such statements. These
forward-looking statements are based on the Company's current
expectations and beliefs concerning future events affecting the
Company and involve known and unknown risks and uncertainties that
may cause the Company's actual results or outcomes to be materially
different from those anticipated and discussed herein. These risks
and uncertainties include, among others, further deterioration to
the global economic and operating environments as a result of
future COVID-19 developments, as well as those discussed in greater
detail in the Company's Annual Report on Form 10-K and the
Company's Quarterly Report on Form 10-Q under the caption "Risk
Factors," and in other documents filed by the Company from time to
time with the Securities and Exchange Commission (the “SEC”). The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this document. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this document, except as required by law.
Public Relations
Contact: Jennifer Rumble, Cercone Brown Company(704)
923-6378 jrumble@cerconebrown.com
Investor Relations Contact: Reed Anderson,
ICR (646) 277-1260 reed.anderson@icrinc.com
Lifevantage (NASDAQ:LFVN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Lifevantage (NASDAQ:LFVN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024